What Happens When You Stop Your GLP-1: The Rebound Data

During the global dulaglutide shortage, researchers in South Korea followed 69 adults with type 2 diabetes whose GLP-1 receptor agonist was abruptly pulled out from under them. These weren't volunteers in a tidy clinical trial — they were patients whose pharmacies simply ran dry, which is exactly the scenario most of us are actually navigating. The team tracked what happened to their blood sugar over the next three months, and the numbers moved fast.

Average HbA1c — the rolling three-month measure of blood glucose — climbed from 7.0% to 8.1% within three months of stopping. Fasting glucose rose from 129 to 156 mg/dL in the same window. To translate: an HbA1c above 8% is the threshold most diabetes guidelines treat as a signal to escalate therapy, not coast. These patients didn't drift — they jumped a category.

Let's be straight about the size: 69 people is small, the analysis is observational, and everyone in it had type 2 diabetes. If you're taking a GLP-1 purely for weight, this isn't your study. The evidence rating here is moderate — directional, not definitive. But the design has a quiet virtue that bigger, glossier trials often lack. Nobody was randomized off their medication; a supply crisis did it for them. That removes a lot of the selection bias that haunts "patients who chose to stop" studies, where the people quitting tend to be the ones already doing well.

The other thing worth noting: the researchers tried to soften the landing. Patients were moved onto alternative diabetes drugs — DPP-4 inhibitors and SGLT-2 inhibitors, both well-established options. The authors concluded those substitutes were insufficient to hold the line on glycemic control. That's the part that should make anyone planning a swap pause and have a real conversation with their clinician, not a Reddit-thread conversation.

Here's where I have to put on the brakes, because the internet will not. This study measured glycemic control, not weight regain. It cannot tell you what will happen to the number on your scale if you stop semaglutide or tirzepatide. The mechanisms overlap — GLP-1 drugs change appetite, gastric emptying, and insulin signaling — but the outcomes are distinct, and conflating them is how bad advice gets made.

What we can say, carefully, is that the metabolic machinery these drugs prop up appears to revert quickly when the drug is withdrawn, at least in people with diabetes. That's consistent with what doctors have been saying out loud for a while: GLP-1s are treatments, not cures. They work while you take them. The body, freed from the medication, tends to return to its prior set point — which is exactly why discontinuation deserves a plan, not a shrug.

Step back for a moment. The reason this paper exists at all is that GLP-1 supply has been genuinely chaotic for two years. People stopped because they couldn't get their drug, not because they were ready. That's the lived experience of a huge slice of patients right now — and it's worth naming, because the discourse around these medications can feel weirdly moralized, as if discontinuation were always a personal choice rather than a logistics failure.

The practical read, for women in the 35–50 window juggling perimenopause, metabolic shifts, and a medication landscape that keeps moving: assume the drug is doing more than you can see, build a relationship with a clinician who will actually monitor you, and don't make discontinuation decisions based on a single TikTok or a single magazine article — including this one.

If you take one thing from this study, let it be the timeline. Three months is fast. Whether you're rationing because the pharmacy is dry, weighing the cost against your grocery bill, or eyeing the exit because you feel "done," you have enough information now to make the next appointment a real one. Bring the numbers. Ask the questions. The rebound, if it comes, is measurable — which means it's also manageable, with the right support.